This is one of the pioneering studies to evaluate the impact of a PCSK9 inhibitor on plaque evolution in patients with symptomatic ICAS, extending beyond the scope of conventional medical therapy. This evidence concerns the gene PCSK9 and familial isolated congenital asplenia.